Alnylam Pharmaceuticals, Inc. (ALNY): Cost of Revenue
$677.17M
Year ended 2025-12-31
$970.74M
Trailing 12 months to 2026-06-30
+69.0%
3-year compound annual growth
+55.6%
5-year compound annual growth
| Period ended | Cost of Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $677.17M | +120.9% | 2026-02-12, From 2025-01-01 |
| 2024-12-31 | $306.51M | +14.3% | 2026-02-12, From 2024-01-01 |
| 2023-12-31 | $268.22M | +91.3% | 2026-02-12, From 2023-01-01 |
| 2022-12-31 | $140.17M | +21.9% | 2025-02-13, From 2022-01-01 |
| 2021-12-31 | $115.00M | +55.0% | 2024-02-15, From 2021-01-01 |
| 2020-12-31 | $74.19M | +196.0% | 2023-02-23, From 2020-01-01 |
| 2019-12-31 | $25.06M | n/m | 2022-02-10, From 2019-01-01 |
| 2018-12-31 | $1.80M | n/a | 2021-02-11, From 2018-01-01 |
| 2017-12-31 | $0 | n/a | 2020-02-13, From 2017-01-01 |
Cost of Revenue at similar companies
| Company | Year ended | Cost of Revenue | Change YoY |
|---|---|---|---|
| Alnylam Pharmaceuticals, Inc. (ALNY) | 2025-12-31 | $677.17M | +120.9% |
| Perrigo Co PLC (PRGO) | 2025-12-31 | $2.76B | -2.5% |
| BioMarin Pharmaceutical Inc (BMRN) | 2025-12-31 | $717.44M | +23.6% |
| United Therapeutics Corp (UTHR) | 2025-12-31 | $384.40M | +24.1% |
| Amneal Pharmaceuticals, Inc. (AMRX) | 2025-12-31 | $1.91B | +7.4% |
| Elanco Animal Health Inc (ELAN) | 2025-12-31 | $2.12B | +5.9% |
| Organon & Co. (OGN) | 2025-12-31 | $2.90B | +8.0% |
| Sarepta Therapeutics, Inc. (SRPT) | 2025-12-31 | $25.50M | n/a |
| Phibro Animal Health Corp (PAHC) | 2026-06-30 | $1.01B | +12.2% |
Compare ALNY, PRGO, BMRN, UTHR side by side · Screen every company in Pharmaceutical Preparations ↗